CRBP
CORBUS Oral Obesity Pill CRB-913 Shows 5% Weight Loss in Phase 1b
Corbus reported statistically significant weight loss at all three doses of its oral CB1 inverse agonist, with a Phase 2 study planned for the first half of 2027.
CRBP
Market-moving news on Corbus Pharmaceuticals (NASDAQ: CRBP): filings, earnings, deals and other events, from REDFILED.